billSRES714Event Thursday, April 30, 2026Analyzed

A resolution supporting the designation of May 10, 2026, as "National Asian American, Native Hawaiian, and Pacific Islander Mental Health Day".

Neutral

Summary

SRES714 is a non-binding resolution designating May 10, 2026, as a mental health awareness day for the AANHPI community. It authorizes no funding, imposes no mandates, and creates no direct market impact. The bill is in early legislative stage with no material effect on any public company's revenue or costs.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.SRES714 is a non-binding resolution with zero funding or regulatory impact.
  • 2.No publicly traded company is affected by this legislation.
  • 3.Investors should not adjust positions based on this bill.

Market Implications

This bill has no market implications. It does not alter the competitive landscape, regulatory environment, or revenue outlook for any sector or company. Retail investors should ignore this legislation for portfolio decisions.

Full Analysis

1) On April 30, 2026, Senator Hirono introduced SRES714, a resolution supporting the designation of May 10, 2026, as 'National Asian American, Native Hawaiian, and Pacific Islander Mental Health Day'. The bill was referred to the Senate Committee on Health, Education, Labor, and Pensions. It is a non-binding resolution with no force of law. 2) The bill contains zero authorized or appropriated funding. It is purely symbolic — it expresses the sense of the Senate but does not create any spending program, tax credit, grant, or regulatory requirement. No money trail exists. 3) Because the resolution imposes no mandates, incentives, or penalties, there are no structural winners or losers among publicly traded companies. Mental health awareness campaigns may indirectly benefit telehealth or behavioral health providers over the long term, but this resolution alone provides no mechanism for revenue growth. 4) No real market data is provided for any ticker. The competitive landscape in behavioral health includes companies like Talkspace (TALK) and Teladoc (TDOC), but this resolution does not affect their business. 5) The bill has no further legislative steps that would change its market impact — it will either pass or not pass as a symbolic resolution. Companion bills HRES1260 and HRES407 are similarly non-binding. No timeline for floor action is available.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.